3Rees JR,Pinner RW,Hajjeh RA,et al.The epidemiological features of invasive mycotic infections in the San Francisco Bay area,1992-1993:results of populationbased laboratory active surveillance[J].Clin Infect Dis,1998,27(5):1138-1147.
4Pfaller MA,Diekema D J,Jones RN,et al.International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program[J].J Clin Microbiol,2001,399(9):3254-3259.
5Arnow PW,Quimosing EM,Beach M.Consequences of intravascular catheter sepsis[J].Clin Infect Dis,1993,16(6):778-784.
6Kauffman CA.Fungal infections[J].Proc Am Thorac Soc,2006,3(1):35-40.
7Bech-Sague C,Jarvis WR.Secular trends in the epidemiology of nosocomial fungal infections in the United States,1980-1990.National Nasocomial Infections Survillance System[J].J Infect Dis,1993,167(5):1247-1251.
8Vincent JL,Anaissie E,Bruining H,et al.Epidemiology diagnosis and treatment of systemic Candida infection in surgical patients under intensive care[J].Intensive Care Med,1998,24(3):206-216.
9Boon ME,Barlow Y,Marres EM,et al.Microwave-stimulated Jones-Marres method for staining fungi in brain tissue of immune compromised patients[J].Methods,1998,15(2):141-149.
2[1]Liebowitz LD, Ashbee HR, Evans EG, et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion[J]. Diagn Microbiol Infect Dis, 2001, 40: 27-33
